Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Prevention of acute sickle cell crisis: review of the NEJM report
source: Practical Pain Management
year: 2016
authors: Leonard Goldstein, Victoria A. Troncoso, Roya Vahdatinia
summary/abstract:A recent article in the New England Journal of Medicine presented the results of a phase 2 clinical trial that found positive results for the efficacy and safety of crizanlizumab, a novel pharmaceutical agent currently in pipeline development by Selexys Pharmaceuticals.
The drug, designed to block the underlying mechanism of acute painful crisis in patients suffering from sickle-cell disease, could be one of the first and most effective medications of its kind. For all the details on the Phase 2 research, read the original Practical Pain Management report.
In this commentary, Leonard B. Goldstein, DDS, PhD, and colleagues review the research and provide their own opinion on the prospect of a novel pharmaceutical agents for patients suffering from sickle cell disease.
read more
+myBinderRelated Content
-
Smartphone App May Help Assess Anemia Using Eyelid PicturesA smartphone app that measures hemoglobi...
-
Potential treatment targeting nitric oxide levels, olinciguat, named orphan drug by FDAThe U.S. Food and Drug Administration ...
-
Q & A Facts on Hydroxyurea for Children With Sickle Cell DiseaseIt is time to rethink hydroxyurea for th...
-
Pattern of Lung Function Is Not Associated with Prior or Future Morbidity in Children with Sickle Cell AnemiaRATIONALE: Patient factors associated wi...
-
Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem MeetingsGamida Cell, a leading cellular and immu...
-
Teen is one of the first ever to get his genes editedhttps://www.youtube.com/watch?v=0xv0CBuj...
-
Imara’s IMR-687 for SCD Receives FDA Rare Pediatric Disease DesignationThe U.S. Food and Drug Administration (F...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.